Cargando…

A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients

Background: The construction of ferroptosis-related lncRNA prognostic models in malignancies has been an intense area of research recently. However, most of the studies focused on the exact expression of lncRNAs and had limited application values. Herein, we aim to establish a novel prognostic model...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiazheng, Xiang, Renshen, Song, Wei, Wu, Jing, Kong, Can, Fu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250987/
https://www.ncbi.nlm.nih.gov/pubmed/35795206
http://dx.doi.org/10.3389/fgene.2022.899419
_version_ 1784739935270469632
author Li, Jiazheng
Xiang, Renshen
Song, Wei
Wu, Jing
Kong, Can
Fu, Tao
author_facet Li, Jiazheng
Xiang, Renshen
Song, Wei
Wu, Jing
Kong, Can
Fu, Tao
author_sort Li, Jiazheng
collection PubMed
description Background: The construction of ferroptosis-related lncRNA prognostic models in malignancies has been an intense area of research recently. However, most of the studies focused on the exact expression of lncRNAs and had limited application values. Herein, we aim to establish a novel prognostic model for gastric cancer (GC) patients and discuss its correlation with immune landscapes and treatment responses. Methods: The present study retrieved transcriptional data of GC patients from the Cancer Genome Atlas (TCGA) database. We identified differentially expressed ferroptosis-related lncRNAs between tumor and normal controls of GC samples. Based on a new method of cyclically single pairing, we constructed a 0 or 1 matrix of ferroptosis-related lncRNA pairs (FRLPs). A risk score signature consisting of 10 FRLPs was established using multi-step Cox regression analysis. Next, we performed a series of systematic analyses to investigate the association of the FRLP model and tumor microenvironment, biological function, and treatment responses. An alternative model to the FRLP risk score signature, the gene set score (GS) model was also constructed, which could represent the former when lncRNA expression was not available. Results: We established a novel prognostic signature of 10 ferroptosis-related lncRNA pairs. High-risk patients in our risk score model were characterized by high infiltration of immune cells, upregulated carcinogenic and stromal activities, and heightened sensitivity to a wide range of anti-tumor drugs, whereas low-risk patients were associated with better responses to methotrexate treatment and elevated immunotherapeutic sensitivity. The practicability of the FRLP risk score model was also validated in two independent microarray datasets downloaded from Gene Expression Omnibus (GEO) using the GS model. Finally, two online dynamic nomograms were built to enhance the clinical utility of the study. Conclusion: In this study, we developed a ferroptosis-related lncRNA pair-based risk score model that did not rely on the exact lncRNA expression level. This novel model might provide insights for the accurate prediction and comprehensive management for GC patients.
format Online
Article
Text
id pubmed-9250987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92509872022-07-05 A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients Li, Jiazheng Xiang, Renshen Song, Wei Wu, Jing Kong, Can Fu, Tao Front Genet Genetics Background: The construction of ferroptosis-related lncRNA prognostic models in malignancies has been an intense area of research recently. However, most of the studies focused on the exact expression of lncRNAs and had limited application values. Herein, we aim to establish a novel prognostic model for gastric cancer (GC) patients and discuss its correlation with immune landscapes and treatment responses. Methods: The present study retrieved transcriptional data of GC patients from the Cancer Genome Atlas (TCGA) database. We identified differentially expressed ferroptosis-related lncRNAs between tumor and normal controls of GC samples. Based on a new method of cyclically single pairing, we constructed a 0 or 1 matrix of ferroptosis-related lncRNA pairs (FRLPs). A risk score signature consisting of 10 FRLPs was established using multi-step Cox regression analysis. Next, we performed a series of systematic analyses to investigate the association of the FRLP model and tumor microenvironment, biological function, and treatment responses. An alternative model to the FRLP risk score signature, the gene set score (GS) model was also constructed, which could represent the former when lncRNA expression was not available. Results: We established a novel prognostic signature of 10 ferroptosis-related lncRNA pairs. High-risk patients in our risk score model were characterized by high infiltration of immune cells, upregulated carcinogenic and stromal activities, and heightened sensitivity to a wide range of anti-tumor drugs, whereas low-risk patients were associated with better responses to methotrexate treatment and elevated immunotherapeutic sensitivity. The practicability of the FRLP risk score model was also validated in two independent microarray datasets downloaded from Gene Expression Omnibus (GEO) using the GS model. Finally, two online dynamic nomograms were built to enhance the clinical utility of the study. Conclusion: In this study, we developed a ferroptosis-related lncRNA pair-based risk score model that did not rely on the exact lncRNA expression level. This novel model might provide insights for the accurate prediction and comprehensive management for GC patients. Frontiers Media S.A. 2022-06-20 /pmc/articles/PMC9250987/ /pubmed/35795206 http://dx.doi.org/10.3389/fgene.2022.899419 Text en Copyright © 2022 Li, Xiang, Song, Wu, Kong and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Li, Jiazheng
Xiang, Renshen
Song, Wei
Wu, Jing
Kong, Can
Fu, Tao
A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title_full A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title_fullStr A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title_full_unstemmed A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title_short A Novel Ferroptosis-Related LncRNA Pair Prognostic Signature Predicts Immune Landscapes and Treatment Responses for Gastric Cancer Patients
title_sort novel ferroptosis-related lncrna pair prognostic signature predicts immune landscapes and treatment responses for gastric cancer patients
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250987/
https://www.ncbi.nlm.nih.gov/pubmed/35795206
http://dx.doi.org/10.3389/fgene.2022.899419
work_keys_str_mv AT lijiazheng anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT xiangrenshen anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT songwei anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT wujing anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT kongcan anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT futao anovelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT lijiazheng novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT xiangrenshen novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT songwei novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT wujing novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT kongcan novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients
AT futao novelferroptosisrelatedlncrnapairprognosticsignaturepredictsimmunelandscapesandtreatmentresponsesforgastriccancerpatients